RxDoctor Payments Data

Jessica Shabo, MD

Child & Adolescent Psychiatry · Newark, NJNPI 1275869612

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 136 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 29.3% of the total. Reporting peaked in 2019 at $1,023 and has fallen 71.2% since, to $295 in 2025.

$2,153in general payments, 2019–2025

Across 136 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$632
  • Otsuka America Pharmaceutical, Inc.$293
  • Sunovion Pharmaceuticals Inc.$169
  • Teva Pharmaceuticals USA, Inc.$152
  • Corium, LLC$147
  • Neos Therapeutics, LP$146
  • plus $614 from 14 others

What the payments were for

  • Food & beverage$2,147100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,153 in reported general payments places this provider in the 85th percentile of 137 child & adolescent psychiatry providers in New Jersey.

See all child & adolescent psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$16,863
Medicare patients
18
Services billed
184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine13$93,391
Bupropion XlBupropion Hcl54$966
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine14$688
Clonazepam124$688
Aripiprazole30$653
Lamotrigine42$623
Trazodone Hcl43$477
Duloxetine Hcl32$466
Sertraline Hcl67$463
Escitalopram Oxalate36$364
Ziprasidone Hcl12$355
Mirtazapine17$221
Temazepam18$203
Lorazepam59$192
Oxcarbazepine11$192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$152$93,39113 claims
Almatica Pharma LLCSertraline Hcl$14$46367 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 137 child & adolescent psychiatry providers in New Jersey.

Other child & adolescent psychiatry in Newark

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →